Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

'VEEP' in children with Hodgkin's disease--a regimen to decrease late sequelae.

M E O'Brien1, C R Pinkerton, J Kingston

  • 1Royal Marsden Hospital, Sutton, Surrey, UK.

British Journal of Cancer
|May 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severity matters: Using network analysis to explain low and high levels of persecutory beliefs.

Schizophrenia research. Cognition·2026
Same author

First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN Experiment.

Physical review letters·2025
Same author

New Constraints on Cosmic Ray-Boosted Dark Matter from the LUX-ZEPLIN Experiment.

Physical review letters·2025
Same author

Dark Matter Search Results from 4.2  Tonne-Years of Exposure of the LUX-ZEPLIN (LZ) Experiment.

Physical review letters·2025
Same author

Constraints on Covariant Dark-Matter-Nucleon Effective Field Theory Interactions from the First Science Run of the LUX-ZEPLIN Experiment.

Physical review letters·2024
Same author

Simple imaging biomarker predicts survival in anal squamous cell cancer treated with curative intent: a UK cohort study.

Clinical radiology·2024
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
Same journal

Can national lung cancer screening programs be implemented without exacerbating social disparities?

British journal of cancer·2026
See all related articles

A new chemotherapy regimen, VEEP, was tested in children with Hodgkin's disease (HD) to reduce long-term side effects. While showing promising initial response rates, the relapse-free survival appears lower than traditional treatments, requiring further investigation.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Hodgkin's disease (HD) treatment in children carries risks of secondary malignancies and infertility.
  • Conventional chemotherapy regimens often utilize alkylating agents, contributing to long-term toxicities.

Purpose of the Study:

  • To evaluate a novel anthracycline-based chemotherapy regimen (VEEP) for pediatric Hodgkin's disease.
  • To assess the efficacy and safety of VEEP, aiming to minimize risks of second malignancies and infertility.

Main Methods:

  • A pilot study involving 44 pediatric patients (aged 2-15 years) with Hodgkin's disease.
  • Treatment consisted of vincristine, epirubicin, etoposide, and prednisolone (VEEP) administered every 3 weeks.
  • Patients included previously untreated and relapsed cases, with a median follow-up of 25 months.

Related Experiment Videos

Main Results:

  • Response rates were 80% in relapsed patients and 88% in previously untreated patients.
  • Complete remission (CR) or unconfirmed CR (CR(u)) was achieved in 62% of untreated patients.
  • The 3-year relapse-free survival rate was 67%, with some relapses observed in both CR and CR(u) groups.

Conclusions:

  • The VEEP regimen demonstrates notable initial response rates in pediatric Hodgkin's disease.
  • Event-free survival appears potentially lower compared to conventional combination therapies.
  • Further follow-up is necessary to confirm the long-term outcomes and salvagability of relapsed patients treated with VEEP.